Lloyds Metals & Energy Ltd (BOM:512455) Q3 2024 Earnings Call Highlights: Record Production ...
Revenue Growth: 11% year-on-year increase for nine months FY '25.
EBITDA Growth: 31% year-on-year increase for nine months FY '25.
Iron Ore Realizations: Improved by 8% year-on-year in Q3 FY '25 to INR 5,894 per ton; 10% year-on-year increase for nine months FY '25 to INR 5,718 per ton.
Iron Ore EBITDA: 21% year-on-year increase in Q3 FY '25 to INR 2,021; 21% year-on-year increase for nine months FY '25 to INR 1,860.
DRI Production: 78,000 tons in Q3 FY '25; 239,000 tons for nine months FY '25.
CapEx: INR 2,700 crores spent in nine months FY '25; total of INR 4,400 crores planned.
Warning! GuruFocus has detected 2 Warning Sign with BOM:512455.
Release Date: January 29, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Lloyds Metals & Energy Ltd (BOM:512455) recorded its highest ever production during the nine-month period, operating at optimum capacity utilization.
The company achieved a 31% year-on-year growth in EBITDA, driven by strong performance in the iron ore and sponge iron segments.
The iron ore segment saw improved realizations per ton, with an 8% year-on-year increase in Q3 FY '25.
Ongoing projects, including the DRI and pellet plant, are nearing completion and are expected to be commissioned by the end of the current quarter or early next quarter.
The company has implemented cost-efficiency measures, ensuring sustainable profits and maintaining competitiveness in the market.
Market conditions for sponge iron remain volatile, impacting profitability despite operational efficiencies.
Power segment volumes remained flat year-on-year, with muted power prices affecting EBITDA.
The company faces potential delays in receiving environmental clearance (EC), which could impact expansion timelines.
There is uncertainty regarding the timeline for the full ramp-up to desired production levels once EC is received.
The company is exposed to market fluctuations and pricing volatility, particularly in the DRI and power segments.
Q: What is the status of the mine's environmental clearance (EC) and when can it be expected? A: The public hearing was held successfully, and the process is now with the district administration. We expect the EC to be finalized within 60 to 70 days. Once received, the expansion can commence shortly thereafter. - Rajesh Gupta, Non-Executive Director
Q: Can you provide guidance on iron ore production for the remainder of the fiscal year? A: We have dispatched 7.87 million tons in the first nine months and expect to reach 10 million tons by the end of the fiscal year, implying approximately 2.2 million tons in the fourth quarter. - Rajesh Gupta, Non-Executive Director
Q: When will the cost savings from the new business structure be realized? A: The benefits will begin from April 1, 2025, following the NCLT order. The savings will be immediate as the business will operate under a consolidated structure. - Riyaz Shaikh, Chief Financial Officer
Q: How long will it take to ramp up production to the desired levels once the EC is in place? A: We are prepared to start mining immediately after EC approval, with machinery in place to achieve 2.2 million tons per month. The pipeline will support evacuation, and we aim to be fully operational within 30 days post-EC. - Rajesh Gupta, Non-Executive Director
Q: What is the timeline for the beneficiation plant and its phases? A: The first phase of the beneficiation plant is expected to be operational by 2027, with subsequent phases following annually. Each phase will add 15 million tons of capacity. - Rajesh Gupta, Non-Executive Director
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
UnitedHealth (UNH) Faces Sell Call Amid Margin Squeeze, Regulatory Risks
UnitedHealth (UNH, Financials) shares gained 1% Monday after newly reinstated CEO Steve Hemsley apologized for the company's first earnings miss since 2008 and vowed to restore shareholder trust at the annual meeting. Warning! GuruFocus has detected 4 Warning Sign with UNH. Hemsley replaced Andrew Witty last month amid fallout from the earnings shortfall and the suspension of full-year guidance due to soaring medical costs in the Medicare Advantage segment. The company also faces pressure from federal investigations and regulatory scrutiny over billing and drug pricing practices. We are well aware we have not fulfilled your expectations or our own, Hemsley told shareholders. We apologize for that performance, and we're humbly determined to earn back your trust and your confidence. Hemsley previously served as CEO from 2006 to 2013. Shareholders approved his new three-year pay package, which includes equity awards valued at $60 million. Proxy firms were split on the vote, with ISS opposing and Glass Lewis supporting the plan. UnitedHealth is reviewing operations across all units, including Optum Rx and UnitedHealthcare. The U.S. Department of Justice is reportedly examining billing practices tied to its integrated Medicare Advantage services, though the company says it has not received a criminal notification. The company's private insurance and 2026 Medicare Advantage plans will be adjusted to account for higher care costs, Hemsley said. The CEO transition follows the December killing of UnitedHealthcare CEO Brian Thompson in New York, which added further disruption to the company's leadership stability. Investors are now watching for updates on regulatory probes, Medicare audits, and Q2 cost trends that could shape UnitedHealth's revised guidance trajectory. This article first appeared on GuruFocus.
Yahoo
3 hours ago
- Yahoo
Essential Thrombocythemia Market to Witness Robust Growth During the Forecast Period (2025-2034) Amid Rising R&D Activity
Beyond PEGASYS, the essential thrombocythemia treatment landscape is evolving with several promising assets in the pipeline. These include BESREMi (ropeginterferon alfa-2b), Bomedemstat (MK-3543/IMG-7289), Pelabresib (CPI-0610), Dencatistat (STP 938), INCA033989, and VAC85135. LAS VEGAS, June 3, 2025 /PRNewswire/ -- Essential thrombocythemia is a chronic form of myeloproliferative neoplasm (MPN) marked by an abnormally high platelet count in the bloodstream. It is most frequently diagnosed in women over 50 and involves the excessive production of platelet precursors in the bone marrow. Common complications include blood clots and bleeding, while less frequent but more serious outcomes in advanced stages can involve progression to myelofibrosis or acute leukemia. As of 2024, approximately 167K individuals in the US were diagnosed with essential thrombocythemia, with about 75% of these cases linked to mutations in the JAK2 gene. During the same year, an estimated 85K patients in the US received first-line treatment for essential thrombocythemia. The primary goal of essential thrombocythemia management is to reduce the risk of vascular complications, such as thrombotic and hemorrhagic events, which are major contributors to illness and death. Treatment approaches are guided by a risk stratification system that classifies patients as either low or high risk for thrombosis. Typically, low-risk individuals are younger and have no history of clotting events, while high-risk patients are generally over 60 years old and have experienced thrombosis in the past. Learn more about the essential thrombocythemia cancer @ New Treatment for Essential Thrombocythemia For low-risk patients, aspirin is recommended, provided there are no major contraindications. However, caution is advised when platelet counts exceed 1,000 × 10⁹/L, as this raises the risk of acquired von Willebrand disease. In such cases, if laboratory findings suggest von Willebrand abnormalities, aspirin should be avoided. Aspirin is also the preferred treatment in patients experiencing microvascular complications like erythromelalgia. In contrast, high-risk patients are typically managed with a combination of antiplatelet and cytoreductive therapies. Hydroxyurea is generally considered the first-line agent for cytoreduction. However, anagrelide may be used as an alternative when hydroxyurea is poorly tolerated or ineffective. At present, only one drug is officially approved for the treatment of essential thrombocythemia, and its use is restricted to Europe. There are currently no FDA-approved therapies for essential thrombocythemia in the United States. PEGASYS, a Type I interferon, is made by pegylating interferon alfa-2a, which involves attaching polyethylene glycol (PEG) chains to the molecule. Find out more on FDA-approved essential thrombocythemia drugs @ Essential Thrombocythemia Treatment Options PEGASYS was previously approved by the European Commission (EC) for treating Chronic Hepatitis B in adults and children over 3, and Chronic Hepatitis C in adults and children over 5, in combination with other medications. In August 2024, pharmaand GmbH announced that the EC had granted a Type II variation approval for PEGASYS, allowing its use as a monotherapy for adults with essential thrombocythemia. Various key players are leading the treatment landscape of essential thrombocythemia, such as pharma&, AOP Orphan Pharmaceuticals AG, Merck Sharp and Dohme, Novartis, Incyte Corporation, and others. Discover which therapies are expected to grab major essential thrombocythemia market share @ Essential Thrombocythemia Market Report Bomedemstat (MK-3543) is an experimental small-molecule drug developed by Merck that irreversibly inhibits LSD1, a key regulator of hematopoietic stem cell proliferation, differentiation, and maturation. The drug is under clinical evaluation for various myeloproliferative neoplasms (MPNs), including essential thrombocythemia, myelofibrosis, and polycythemia vera. In 2018, Bomedemstat was granted Orphan Drug Designation (ODD) for essential thrombocythemia treatment. In January 2020, Imago BioSciences received Fast Track Designation (FTD) from the US FDA for bomedemstat for the same indication. By November 2022, Merck announced its acquisition of Imago BioSciences, a clinical-stage biotechnology company focused on bomedemstat for myelofibrosis treatment, for $36 per share in cash, totaling approximately $1.35 billion. This strategic move aimed to strengthen Merck's hematology portfolio and establish its presence in the growing myelofibrosis market. PharmaEssentia is advancing ropeginterferon alfa-2b (P1101) for essential thrombocythemia, offering a biweekly injection regimen aimed at improving tolerability and patient adherence, thereby enhancing therapeutic outcomes. A global Phase III clinical trial for essential thrombocythemia is currently in progress. Participants who respond positively during the initial study period will continue into an extension phase for long-term evaluation. Pelabresib, another investigational therapy, is a selective small molecule targeting BET (bromodomain and extra-terminal domain) proteins, which are involved in gene regulation associated with hematologic malignancies. The ongoing Phase II MANIFEST trial (NCT02158858) is assessing its efficacy in patients with myelofibrosis and high-risk ET through an open-label study. In February 2024, MorphoSys entered into a Business Combination Agreement with Novartis AG, reflecting Novartis's plan to launch a voluntary public takeover offer for all outstanding MorphoSys bearer shares without nominal value. Discover more about drugs for essential thrombocythemia in development @ Essential Thrombocythemia Clinical Trials The anticipated launch of these emerging therapies for essential thrombocythemia are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the essential thrombocythemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for essential thrombocythemia is expected to grow from USD 417 million in the 7MM in 2024 at a significant CAGR by 2034. The market size of essential thrombocythemia is expected to grow due to several factors, including an increase in the prevalent pool, the expected entry of emerging therapies with novel targets, and attractive pricing in the 7MM. DelveInsight's latest published market report, titled as Essential Thrombocythemia Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the essential thrombocythemia country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The essential thrombocythemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases Symptom-specific Cases Gender-specific Cases Mutation-specific Cases Risk-specific Cases Age-specific Cases Total Treated Cases The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM essential thrombocythemia market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this essential thrombocythemia market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the essential thrombocythemia market. Also, stay abreast of the mitigating factors to improve your market position in the essential thrombocythemia therapeutic space. Related Reports Essential Thrombocythemia Epidemiology Essential Thrombocythemia Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the essential thrombocythemia epidemiology trends. Essential Thrombocythemia Pipeline Essential Thrombocythemia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key essential thrombocythemia companies, including PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals, among others. Polycythemia Vera Market Polycythemia Vera Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key polycythemia vera companies, including IIncyte, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience, Disc Medicine, GluBio Therapeutics, among others. Polycythemia Vera Pipeline Polycythemia Vera Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key polycythemia vera companies, including Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, Perseus Proteomics, Agios Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP
Yahoo
3 hours ago
- Yahoo
UnitedHealth (UNH) Faces Sell Call Amid Margin Squeeze, Regulatory Risks
UnitedHealth (UNH, Financials) shares gained 1% Monday after newly reinstated CEO Steve Hemsley apologized for the company's first earnings miss since 2008 and vowed to restore shareholder trust at the annual meeting. Warning! GuruFocus has detected 4 Warning Sign with UNH. Hemsley replaced Andrew Witty last month amid fallout from the earnings shortfall and the suspension of full-year guidance due to soaring medical costs in the Medicare Advantage segment. The company also faces pressure from federal investigations and regulatory scrutiny over billing and drug pricing practices. We are well aware we have not fulfilled your expectations or our own, Hemsley told shareholders. We apologize for that performance, and we're humbly determined to earn back your trust and your confidence. Hemsley previously served as CEO from 2006 to 2013. Shareholders approved his new three-year pay package, which includes equity awards valued at $60 million. Proxy firms were split on the vote, with ISS opposing and Glass Lewis supporting the plan. UnitedHealth is reviewing operations across all units, including Optum Rx and UnitedHealthcare. The U.S. Department of Justice is reportedly examining billing practices tied to its integrated Medicare Advantage services, though the company says it has not received a criminal notification. The company's private insurance and 2026 Medicare Advantage plans will be adjusted to account for higher care costs, Hemsley said. The CEO transition follows the December killing of UnitedHealthcare CEO Brian Thompson in New York, which added further disruption to the company's leadership stability. Investors are now watching for updates on regulatory probes, Medicare audits, and Q2 cost trends that could shape UnitedHealth's revised guidance trajectory. This article first appeared on GuruFocus.
